China

Medical infrastructure and disease prevention have been China’s healthcare focuses since 2019, to counter the growing incidence of chronic diseases related to lifestyle habits.

A positive effect of the coronavirus on China’s health industry was the improvement of in-vitro diagnostics development, with many local manufactures launching nucleic acid tests, serology tests, and point-of-care tests.

Roche played an integral role in helping China understand how diagnostics could be the first line of defense against infections, and supported multiple stakeholders, from the authorities to labs and healthcare providers, to trial testing solutions and conduct epidemiologic investigations around the virus to better shape China’s pandemic containment strategy.

Using research to battle COVID-19

• Collaborating with medical associations and key opinion leaders to provide the knowledge and data required to combat COVID-19, we integrated internal and external expert resources to develop the clinical studies necessary to create solutions to the medical challenges China faced. .
  

Reducing wait time with for heart attack patients with MyLab+ER

• We launched the MyLab+ER campaign to implement more efficient diagnosis and treatment of ER patients, slashing the turnaround time from 3-4 hours to 1-2 hours.

Promoting safer lung cancer treatment with Tumor Marker Tests

• Over a three-year period, we educated over 1,000 healthcare professionals in top class “3A” hospitals on the use of tumour marker tests, and plan to educate an additional 500 healthcare practitioners each year.